Investing Profile

Mark Chin

InvestorVC
Managing Director at Arix Bioscience
arixbioscience.com/team/mark-...New York City
Photo of Mark Chin, Managing Director at Arix Bioscience
Your Intro Paths to Mark Chin

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

Find Mark Chin on

cb
Current Investing Position
Arix Bioscience Managing Director
Investment Range
$100K - $5.0M
Sweet Spot
$1.5M
Investments On Record
12

Mark Chin is on these Sector & Stage Rankings

Mark Chin's Investments On Record (9)

CompanyStageDateRound SizeTotal Raised
Vicebio
Series BSep 2024$100M
$100M
Evommune
Series BApr 2023$50M
$260M
Co-investors: Derek DiRocco (RA Capital), Ash Khanna (Pivotal bioVenture Partners), Rob Hopfner (Pivotal bioVenture Partners)
Ensoma
Series BJan 2023$85M
$210M
Co-investors: Kush Parmar (5am Ventures), Stephen Knight (F-Prime Capital Partners), Kouki Harasaki (Bioluminescence Ventures)
Disc Medicine
Post Ipo EquityAug 2022$54M
Post Ipo EquitySep 2021$90M
$440M
Co-investors: Mona Ashiya (OrbiMed), Kevin Bitterman (Atlas Venture)
VelosBio
Series BJul 2020$140M
Series AOct 2018$58M
$200M
Co-investors: Joseph Anderson (Soffinova Partners)
Imara
Series BMar 2019$63M
$63M
Co-investors: David Bonita (OrbiMed), Joseph Anderson (Soffinova Partners)
Harpoon Therapeutics
Series CNov 2018$70M
Series BMay 2017$45M
$120M
Co-investors: Luke Evnin (MPM Capital)
Aura Biosciences
Series CDec 2017$30M
$130M
Co-investors: Joël Jean-Mairet (Ysios Capital)